Magnetically labeled human natural killer cells, accumulated in vitro by an external magnetic force, are effective against HOS osteosarcoma cells

International Journal of Oncology

Volumn 27, Issue 4, 2005, Pages 965-971

  Nakashima, Yuko ^a   Deie, Masat Aka ^a   Yanada, Shinobu ^a   Sharman, Patrick ^a   Ochi, Mitsuo ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Immunotherapy; Magnetic targeting; NK cell; Osteo sarcoma

Indexed keywords

ANTINEOPLASTIC AGENT; CASP3 PROTEIN, HUMAN; CASPASE; CASPASE 3; CD3 ANTIGEN; CD56 ANTIGEN; INTERLEUKIN 2;

APOPTOSIS; ARTICLE; BIOSYNTHESIS; CELL SEPARATION; CELL STRAIN K 562; CYTOLOGY; CYTOTOXICITY; FLOW CYTOMETRY; HUMAN; IMMUNOTHERAPY; IN VITRO STUDY; MAGNETISM; METABOLISM; METHODOLOGY; NATURAL KILLER CELL; OSTEOSARCOMA; TIME; TUMOR CELL LINE;

ANTIGENS, CD3; ANTIGENS, CD56; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CASPASES; CELL LINE, TUMOR; CELL SEPARATION; CYTOTOXICITY, IMMUNOLOGIC; FLOW CYTOMETRY; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; K562 CELLS; KILLER CELLS, NATURAL; MAGNETICS; OSTEOSARCOMA; TIME FACTORS;

EID: 29144529616     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.27.4.965     Document Type: Article

References (40)

1. Yannelli JR and Wroblewski JM: On the road to a tumor cell vaccine: 20 years of cellular immunotherapy. Vaccine 23: 97-113, 2004.
2. Rosenberg SA, Lotze MT, Muul LM, et al: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316: 889-897, 1987.
3. Fisher RI, Coltman CA Jr, Doroshow JH, et al. Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial. Ann Intern Med 108: 518-523, 1988.
4. Huber CH and Wolfel T: Immunotherapy of cancer: from vision to standard clinical practice. J Cancer Res Clin Oncol 130: 367-374, 2004.
5. Baxevanis CN and Papamichail M: Targeting of tumor cells by lymphocytes engineered to express chimeric receptor genes. Cancer Immunol Immunother 53: 893-903, 2004.
6. Blattman JN and Greenberg PD: Cancer immunotherapy: a treatment for the masses. Science 305: 200-205, 2004.
7. Hafeli UO: Magnetically modulated therapeutic systems. Int J Pharm 277: 19-24, 2004.
8. Kronick PL, Campbell GL and Joseph K: Magnetic microspheres prepared by redox polymerization used in a cell separation based on gangliosides. Science 200: 1074-1076, 1978.
9. Hill JM, Dick AJ, Raman VK, et al. Serial cardiac magnetic resonance imaging of injected mesenchymal stem cells. Circulation 108: 1009-1014,2003.
10. Arbab AS, Yocum GT, Kalish H, et al: Efficient magnetic cell labeling with protamine sulfate complexed to ferumoxides for cellular MRI. Blood 104: 1217-1223, 2004.
11. Ochi M, Adachi N, Nobuto H, Yanada S, Ito Y and Agung M: Articular cartilage repair using tissue engineering technique - novel approach with minimally invasive procedure. Artificial Organs 28: 28-32, 2004.
12. Arbab AS, Jordan EK, Wilson LB, Yocum GT, Lewis BK and Frank JA: In vivo trafficking and targeted delivery of magnetically labeled stem cells. Hum Gene Ther 15: 351-360, 2004.
13. Ito A, Takizawa Y, Honda H, Hata K, Kagami H, Ueda M and Kobayashi T: Tissue engineering using magnetite nanoparticles and magnetic force: heterotypic layers of cocultured hepatocytes and endothelial cells. Tissue Eng 10: 833-840, 2004.
14. Ito A, Hayashida M, Honda H, Hata K, Kagami H, Ueda M and Kobayashi T: Construction and harvest of multilayered keratinocyte sheets using magnetite nanoparticles and magnetic force. Tissue Eng 10: 873-880, 2004.
15. O'Shea J and Ortaldo JR: The biology of natural killer cells: Insights into the molecular basis of function. In: The Natural Killer Cell. Lewis CE and McGee JO (eds.) IRL Press, Oxford, pp2-40, 1992.
16. Moretta A, Bottino C, Mingari MC, Biassoni R and Moretta L: What is a natural killer cell? Nat Immunol 3: 6-8, 2002.
17. Shaw AR, Bleackley RC, Merryweather JP and Barr PJ: Modulation of human natural killer cell activity by recombinant human interleukin 2. Cell Immunol 91: 193-200, 1985.
18. Miltenyi S, Muller W, Weichel W and Radbruch A: High gradient magnetic cell separation with MACS. Cytometry 11: 231-238,1990.
19. Naume B, Nonstad U, Steinkjer B, Funderud S, Smeland E and Espevik T: Immunomagnetic isolation of NK and LAK cells. J Immunol Methods 136: 1-9, 1991.
20. Pflueger E, Mueller EA and Anderer FA: Preservation of cytotoxic function during multi-cycle immunomagnetic cell separations of human NK cells using a new type of magnetic bead. J Immunol Methods 129: 165-173, 1990.
21. Juliusson PB and Ogmundsdottir HM: Suppression of target cell proliferation by natural killer cells. Scand J Immunol 32: 471-482, 1990.
22. Funk J, Schmitz G, Failing K and Burkhardt E: Natural killer (NK) and lymphokine-activated killer (LAK) cell functions from healthy dogs and 29 dogs with a variety of spontaneous neoplasms. Cancer Immunol Immunother 54: 87-92, 2005.
23. Tarozzi A, Mariani E and Facchini A: In vitro cytolytic activity of human NK cells against osteosarcoma cell lines. Boll Soc Ital Biol Sper 71: 221-226, 1995.
24. Mariani E, Tarozzi A, Meneghetti A, Tadolini M and Facchini A: Lytic activity of IL-2 and IL-12 stimulated NK cells against HOS osteosarcoma cell line. Boll Soc Ital Biol Sper 72: 21-27, 1996.
25. Mariani E, Tarozzi A, Meneghetti A, Cattini L and Facchini A: Human osteosarcoma cell susceptibility to natural killer cell lysis depends on CD54 and increases after TNF alpha incubation. FEBS Lett 406: 83-88, 1997.
26. Mariani E, Tarozzi A, Meneghetti A, Cattini L and Facchini A: TNF-a but not IL-1 and IL-6 modifies the susceptibility of human osteosarcoma cells to NK lysis. Int J Oncol 13: 349-353, 1998.
27. Meneghetti A, Mariani E, Santi S, Riccio M, Cattini L, Paoletti S and Facchini A: NK binding capacity and lytic activity depend on the expression of ICAM-1 on target bone tumours. Int J Oncol 15:909-914, 1999.
28. Mariani E, Meneghetti A, Tarozzi A, Cattini L and Facchini A: Interleukin-12 induces efficient lysis of natural killer-sensitive and natural killer-resistant human osteosarcoma cells: the synergistic effect of interleukin-2. Scand J Immunol 51: 618-625, 2000.
29. Liebau C, Merk H, Schmidt S, et al: Interleukin-12 and interleukin-18 change ICAM-I expression, and enhance natural killer cell mediated cytolysis of human osteosarcoma cells. Cytokines Cell Mol Ther 7: 135-142, 2002.
30. Kobayashi Y, Sudo T, Matsushita N, et al Preparation of NK-enriched LAK cells - their potential cytotoxic and ADCC activities. Gan To Kagaku Ryoho 30: 1776-1779, 2003.
31. Harada H, Saijo K, Watanabe S, Tsuboi K, Nose T, Ishiwata I and Ohno T: Selective expansion of human natural killer cells from peripheral blood mononuclear cells by the cell line, HFWT. Jpn J Cancer Res 93: 313-319, 2002.
32. Saini S, Stark DD, Hahn PF, Wittenberg J, Brady TJ and Ferrucci JT Jr: Ferrite particles: a superparamagnetic MR contrast agent for the reticuloendothelial system. Radiology 162:211-216,1987.
33. Jordan A, Wust P, Fahling H, John W, Hinz A and Felix R: Inductive heating of ferrimagnetic particles and magnetic fluids: physical evaluation of their potential for hyperthermia. Int J Hyperthermia 9: 51-68, 1993.
34. Lubbe AS, Bergemann C, Riess H, et al Clinical experiences with magnetic drug targeting: a phase I study with 4′-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res 56: 4686-4693, 1996.
35. Kubo T, Sugita T, Shimose S, Nitta Y, Ikuta Y and Murakami T: Targeted delivery of anticancer drugs with intravenously administered magnetic liposomes in osteosarcoma-bearing hamsters. Int J Oncol 17: 309-315, 2000.
36. Kubo T, Sugita T, Shimose S, Nitta Y, Ikuta Y and Murakami T: Targeted systemic chemotherapy using magnetic liposomes with incorporated adriamycin for osteosarcoma in hamsters. Int J Oncol 18: 121-125,2001.
37. Nobuto H, Sugita T, Kubo T, Shimose S, Yasunaga Y, Murakami T and Ochi M: Evaluation of systemic chemotherapy with magnetic liposomal doxorubicin and a dipole external electromagnet. Int J Cancer 109: 627-635, 2004.
38. Hafeli UO, Sweeney SM, Beresford BA, Sim EH and Macklis RM: Magnetically directed poly(lactic acid) 90Ymicrospheres: novel agents for targeted intracavitary radiotherapy. J Biomed Mater Res 28: 901-908, 1994.
39. Scherer F, Anton M, Schillinger U, et al: Magnetofection: enhancing and targeting gene delivery by magnetic force in vitro and in vivo. Gene Ther 9: 102-109, 2002.
40. Hirao K, Sugita T, Kubo T, Igarashi K, Tanimoto K, Murakami T, Yasunaga Y and Ochi M: Targeted gene delivery to human osteosarcoma cells with magnetic cationic liposomes under a magnetic field. Int J Oncol 22: 1065-1071, 2003. Technology